Clinical trials: Insulin Resistance, Diabetes
Insulin Resistance
Effects of Novel Fiber on Glucose Homeostasis in Individuals at Risk for Diabetes
This study will critically evaluate the effects of a novel dietary fiber administered to subjects at high risk for developing diabetes to determine if this intervention will improve insulin sensitivity compared to control product…
- Trial name
- NCT00820807
- Testing
- Novel dietary fiber
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cargill
Non-Diabetic, Females Who Are Not Pregnant or Breast Feeding
The Wellness Transformation Network Pilot Study
The purpose of the study is to establish a Standard Operating Procedure (SOP) for the screening of pathologies associated with prediabetes and type 2 diabetes.
- Trial name
- NCT05314036
- Testing
- Standardized test meal
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- SciMar Ltd.
Insulin Resistance
Efficacy Pilot Study of Triflusal in the Attenuation of Insulin Resistance in Human Obesity
To explore the efficacy of triflusal in the attenuation of insulin resistance in human obesity. Triflusal is a salicylate compound approved in several countries as antithrombotic agent (antiplatelet).
- Trial name
- NCT00162799
- Testing
- Triflusal (DCI)
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- J. Uriach and Company
Diabetes Mellitus
Effect of Varying the Protein and Dietary Fiber Content of Energy Bars on Their Glycemic and Insulinemic Impact
The purpose of this study was to determine the effect of changing the amounts of resistant starch, whey protein and sugar on the blood glucose and insulin responses elicited by energy bars.
- Trial name
- Solstice (NCT02537587)
- Testing
- Control 1, Control 2, 15/0
- Where
- Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Glycemic Index Laboratories, Inc
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes
The purpose of this study is to investigate (1) the effect of topiramate on insulin sensitivity in overweight or obese patients with type 2 diabetes mellitus and (2) the safety of topiramate in type 2 diabetic patients.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00236626
- Testing
- topiramate
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 1 Diabetes
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
- Trial name
- ABC (NCT05243628)
- Testing
- Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mannkind Corporation
Type 2 Diabetes Mellitus
CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy
Patients initiating injectable therapy for type 2 diabetes (insulin or exenatide) in usual clinical practice will be enrolled and followed up for two years in order to describe actual practice with regards to the time on initial…
- Trial name
- NCT00635492
- Testing
- exenatide, any human insulin or analog insulin(s) given in any regimen by subcutaneous injection
- Where
- 96 sites in Denmark, France and 3 more
- Volunteers
- 2,515 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
This is an Open-label, randomized study in Type 1 diabetics looking at exposure and response (PK/PD) of TI using GEN2C Inhaler versus rapid acting analog.
- Trial name
- NCT01544881
- Testing
- Technosphere Insulin Inhalation Powder, Rapid Acting Analog
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mannkind Corporation
Diabetes
Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients
The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to Nateglinide for the treatment of type 2 diabetes.
- Trial name
- NCT00461617
- Testing
- Mitiglinide
- Volunteers
- 291 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Efficacy of DLBS-32 in Subjects With Type-II Diabetes Mellitus
The purpose of this study is to investigate clinical efficacy and safety of DLBS 32 in the management of subjects with type-II-diabetes mellitus and to determine the minimal effective dose of DLBS 32 for subjects with…
- Trial name
- NCT01005069
- Testing
- DLBS-32
- Where
- 2 sites in Indonesia
- Volunteers
- 72 people
- Sponsor
- Dexa Medica Group
Diabetes Mellitus
Safety and Efficacy Study of Alogliptin on Glycemic Control in Subjects With Type 2 Diabetes.
The purpose of this study is to determine the safety and efficacy of alogliptin, once daily (QD), compared to diet and exercise, sulfonylurea, metformin and a combination of sulfonylurea and metformin for treating subjects with…
- Trial name
- NCT00755846
- Testing
- Alogliptin
- Volunteers
- 265 people
- Sponsor
- Takeda
Diabetes Mellitus Type 2
Lispro Mix 25 vs. Glargine in Type 2 Diabetics
In patients with type 2 diabetes who have not been on insulin therapy before the study will achieve better glycemic control by the treatment regiment consisting of two times daily insulin lispro mix 25 than by the treatment…
- Trial name
- IOOL (NCT00551356)
- Testing
- Insulin lispro mix 25, Glargine
- Where
- Mexico
- Volunteers
- 53 people
- Sponsor
- Eli Lilly and Company
Healthy
Identification of Biometric Marker(s) Capable of Detecting Early Prediabetes: Clinical Trial 1
The proposed clinical trial is a controlled study of n=24 healthy adult individuals tested in both the Meal-Induced Insulin Sensitization (MIS) state and, following atropine blockade, Absence of Meal-Induced Insulin Sensitization…
- Trial name
- NCT04625088
- Testing
- Standardized liquid test meal, Atropine + Standardized liquid test meal
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- SciMar Ltd.
Type 2 Diabetes Mellitus
Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin
In this study, the effect of miglitol on daily plasma glucose will be evaluated in type 2 diabetic patients treated with insulin.
- Trial name
- NCT00213122
- Testing
- miglitol
- Where
- Japan
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Diabetes
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2…
- Trial name
- NCT06767735
- Testing
- GZR4, Insulin Glargine U100
- Where
- China
- Volunteers
- 580 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus
Many drugs used for the treatment of Type 2 Diabetes Mellitus cause the body to retain water. This study will assess whether or not GW677954 causes the body to retain fluid.
- Trial name
- NCT00437164
- Testing
- Insulin, Oral GW677954 Capsules (15 mg)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02158078
- Testing
- PaQ® Insulin Delivery Device
- Where
- Austria
- Volunteers
- 8 people
- Sponsor
- CeQur Corporation